Exagen Inc.
NASDAQ:XGNMedical - Diagnostics & Research
+$0.16 today
- Market cap
- $99.50M
- Beta
- 2.02
- P/E (TTM)
- -5.2
- EPS (TTM)
- -$0.85
Volume 0.47M
Average 0.39M
XGN Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Exagen Inc.NASDAQ: XGN
Gross Margin · Q1 FY2026 · quarter ended Mar 2026
Gross margin holds steady near 59.0%
Gross margin was 59.0% in Q1 FY2026, up 0.1 pp from a year earlier. On a trailing-twelve-month basis it was 58.3%, down 1.0 pp year over year. Over 3 fiscal years it widened by 11.4 pp.
Context
- Gross margin widened in 2 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 58.3%
- Year-over-year change
- -1.2pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 58.3% | -1.2pp |
| FY2024 | 2024-12-31 | 59.5% | +3.5pp |
| FY2023 | 2023-12-31 | 56.1% | +9.2pp |
| FY2022 | 2022-12-31 | 46.9% | -10.5pp |
| FY2021 | 2021-12-31 | 57.4% | — |
Gross Margin vs competitors
How XGN compares with its peers on the latest reported figures
- XGN's LTM Mar 2026 gross margin of 58.3% is the 7th highest of the 11 companies compared; the peer median is 68.0%.
- Its year-over-year change of -1.0 pp is the 7th highest of 10, against a peer median of +0.5 pp.
- Over three fiscal years its change of +11.4 pp compares with a peer median of +3.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
BIOABioAge Labs, Inc. | LTM Mar 2026 | 99.4% | -0.6 pp | — |
| LTM Mar 2026 | 92.5% | -1.0 pp | +3.5 pp | |
| LTM Mar 2026 | 91.2% | +0.8 pp | +4.0 pp | |
| LTM Mar 2026 | 86.2% | +0.5 pp | +3.5 pp | |
| LTM Mar 2026 | 76.3% | +55.8 pp | +13.5 pp | |
| FY2025 | 59.7% | -1.5 pp | +7.9 pp | |
| LTM Mar 2026 | 58.3% | -1.0 pp | +11.4 pp | |
| LTM Mar 2026 | 53.9% | +0.5 pp | -12.9 pp | |
| LTM Jun 2026 | 42.9% | -1.0 pp | +2.0 pp | |
| LTM Mar 2026 | 33.3% | +12.3 pp | -9.0 pp | |
| LTM Mar 2026 | 31.2% | — | -3.8 pp | |
| Peer median (excluding XGN) | 68.0% | +0.5 pp | +3.5 pp | |
Competitors are the stored peer set for XGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 48.3M | 45.56M | 52.55M | 55.64M | 66.58M |
| Cost of Revenue | 20.59M | 24.21M | 23.09M | 22.53M | 27.78M |
| Gross Profit | 27.71M | 21.35M | 29.46M | 33.11M | 38.8M |
| Gross Margin | 57.4% | 46.9% | 56.1% | 59.5% | 58.3% |
| Research & Development | 7.24M | 9.88M | 4.87M | 5.38M | 6.25M |
| Selling, General & Admin | 44.54M | 52.02M | 47.43M | 41.37M | 46.62M |
| Operating Expenses | 51.78M | 67.4M | 52.29M | 46.75M | 52.87M |
| Depreciation & Amortization | 948K | 1.56M | 2.17M | 1.72M | 2.12M |
| EBITDA | (23.1M) | (43.66M) | (19.15M) | (11.15M) | (13.46M) |
| EBITDA Margin | -47.8% | -95.8% | -36.4% | -20.0% | -20.2% |
| Operating Income | (24.07M) | (46.05M) | (22.84M) | (13.64M) | (14.07M) |
| Operating Margin | -49.8% | -101.1% | -43.5% | -24.5% | -21.1% |
| Interest Income | 16K | 830K | 1.52M | 767K | 289K |
| Interest Expense | 2.63M | 2.45M | 2.34M | 2.23M | 4.32M |
| Other Income / Expenses | (2.61M) | (1.62M) | (819K) | (1.47M) | (5.83M) |
| Income Before Tax | (26.68M) | (47.67M) | (23.66M) | (15.1M) | (19.9M) |
| Pre-Tax Margin | -55.2% | -104.6% | -45.0% | -27.1% | -29.9% |
| Income Tax Expense | 175K | (282K) | 33K | 12K | 51K |
| Net Income | (26.85M) | (47.39M) | (23.69M) | (15.12M) | (19.95M) |
| Net Margin | -55.6% | -104.0% | -45.1% | -27.2% | -30.0% |
| EPS (Basic) | (1.68) | (2.77) | (1.34) | (0.83) | (0.93) |
| EPS (Diluted) | (1.68) | (2.77) | (1.34) | (0.83) | (0.93) |
| Weighted Avg Shares | 15.97M | 17.08M | 17.68M | 18.2M | 21.56M |
| Weighted Avg Shares (Diluted) | 15.97M | 17.08M | 17.68M | 18.2M | 21.56M |
Exagen Inc.
NASDAQ:XGN
Intrinsic Alpha fair value
Locked
Current Price
$3.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.